Himmelfarb J, Tolkoff Rubin N, Chandran P, Parker R A, Wingard R L, Hakim R
Maine Medical Center, Portland 04102, USA.
J Am Soc Nephrol. 1998 Feb;9(2):257-66. doi: 10.1681/ASN.V92257.
The mortality of patients with acute renal failure (ARF) remains high, and in several large studies approaches 60%. This mortality is particularly high in patients with ARF who require dialysis and has not changed substantially over several years, despite the introduction of major advances in monitoring and treatment. Increasing prevalence of comorbidities has been suggested as the major factor in this persistently high mortality. This study investigates the potential role of the dialysis membrane on patient outcome in a prospective multicenter study of 153 patients with ARF requiring dialysis. The membrane assignment was made in alternating order and was limited to membranes with low complement activation (Biocompatible [BCM]) and cellulosic, high complement activation (Bioincompatible [BICM]). Both types of membranes were low-flux membranes. Patients were dialyzed with the assigned membrane until recovery, discharge from hospital, or death. The severity of illness of each patient was assessed using the APACHE II score at the time of initiation of dialysis. A logistic regression analysis was used to adjust for the APACHE II score. The results of the study showed a statistically significant difference in survival (57% in patients on BCM, 46% in patients on BICM; P = 0.03) and in recovery of renal function (64% in patients on BICM and 43% in patients on BICM; P = 0.001). These differences were particularly marked in the patients who were nonoliguric (>400 ml/d of urine output) at initiation of the study. In the subset of patients who were nonoliguric at the start of dialysis, a larger fraction (70%) became oliguric after initiating dialysis on a BICM membrane, in contrast to 44% who were initiated on a BCM membrane (P = 0.03). It is concluded that the biocompatibility of the dialysis membrane plays a role in the outcome of patients with ARF, particularly those who are nonoliguric at the time of initiation of dialysis.
急性肾衰竭(ARF)患者的死亡率仍然很高,在几项大型研究中接近60%。在需要透析的ARF患者中,这一死亡率尤其高,并且尽管在监测和治疗方面取得了重大进展,但在过去几年中并没有实质性变化。共病患病率的增加被认为是导致这一持续高死亡率的主要因素。本研究在一项对153例需要透析的ARF患者进行的前瞻性多中心研究中,调查了透析膜对患者预后的潜在作用。膜的分配按交替顺序进行,且仅限于补体激活低的膜(生物相容性膜[BCM])和纤维素性、补体激活高的膜(生物不相容性膜[BICM])。两种类型的膜都是低通量膜。患者使用分配的膜进行透析,直至康复、出院或死亡。在开始透析时,使用急性生理与慢性健康状况评分系统II(APACHE II)对每位患者的病情严重程度进行评估。采用逻辑回归分析对APACHE II评分进行校正。研究结果显示,在生存率方面存在统计学显著差异(使用BCM膜的患者为57%,使用BICM膜的患者为46%;P = 0.03),在肾功能恢复方面也存在差异(使用BICM膜的患者为64%,使用BICM膜的患者为43%;P = 0.001)。这些差异在研究开始时非少尿(尿量>400 ml/d)的患者中尤为明显。在透析开始时非少尿的患者亚组中,更大比例(70%)的患者在使用BICM膜开始透析后变为少尿,相比之下,使用BCM膜开始透析的患者中这一比例为44%(P = 0.03)。得出的结论是,透析膜的生物相容性在ARF患者的预后中起作用,尤其是在透析开始时非少尿的患者中。